Literature DB >> 12023517

Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide.

Ruth A Ross1, Susan J Craib, Lesley A Stevenson, Roger G Pertwee, Andrea Henderson, John Toole, Heather C Ellington.   

Abstract

Anandamide can be metabolized by cyclooxygenase-2 to produce prostaglandin E(2) (PGE(2)) ethanolamide. The purpose of this study was to investigate the pharmacology of this novel compound. Radioligand binding experiments in membranes from human embryonic kidney cells transfected with PGE(2) receptor subtypes EP(1), EP(2), EP(3), and EP(4) revealed that PGE(2) ethanolamide has pK(i) values of 5.61 +/- 0.1, 6.33 +/- 0.01, 6.70 +/- 0.13, and 6.29 +/- 0.06, respectively, compared with 8.31 +/- 0.16, 9.03 +/- 0.04, 9.34 +/- 0.06, and 9.10 +/- 0.04 for PGE(2). PGE(2) inhibits electrically evoked contractions of the guinea pig vas deferens (EP(3) receptor-mediated), with a pEC(50) value of 9.09 +/- 0.06, compared with that of 7.38 +/- 0.09 for PGE(2) ethanolamide. In the guinea pig trachea, 100 nM PGE(2) and 1 microM PGE(2) ethanolamide produced contractions of 51.8 +/- 10.6 and 38.9 +/- 5.6% (of the histamine E(max)), respectively. The EP(1) receptor antagonist SC-51089 (10 microM) prevented the contractions induced by both compounds. In the presence of 10 microM 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide, monohydrochloride (SC-51089), PGE(2) caused a concentration-related relaxation of histamine-induced contractions of this tissue (EP(2) receptor-mediated), the pEC(50) value being 8.29 +/- 0.17 compared with that of 7.11 +/- 0.18 for PGE(2) ethanolamide. In the rabbit jugular vein, PGE(2) induces relaxation (EP(4) receptor-mediated) with a pEC(50) of 9.35 +/- 0.25, compared with 7.05 +/- 0.4 for PGE(2) ethanolamide. In dorsal root ganglion neurons in culture, 3 microM PGE(2) ethanolamide evoked an increase in intracellular calcium concentration in 21% of small-diameter capsaicin-sensitive neurons. We conclude that this compound is pharmacologically active, however its physiological relevance has yet to be established.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023517     DOI: 10.1124/jpet.301.3.900

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

Review 1.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

2.  Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription.

Authors:  Yanbin Liang; Chen Li; Victor M Guzman; William W Chang; Albert J Evinger; Jozelyn V Pablo; David F Woodward
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

Review 3.  Therapeutic implications of disorders of cell death signalling: membranes, micro-environment, and eicosanoid and docosanoid metabolism.

Authors:  J Davidson; D Rotondo; M T Rizzo; H A Leaver
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 4.  A Double Whammy: Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) To Treat Pain and Inflammation.

Authors:  Rita Scarpelli; Oscar Sasso; Daniele Piomelli
Journal:  ChemMedChem       Date:  2015-10-21       Impact factor: 3.466

Review 5.  Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.

Authors:  Daniel J Hermanson; Joyonna C Gamble-George; Lawrence J Marnett; Sachin Patel
Journal:  Trends Pharmacol Sci       Date:  2014-05-18       Impact factor: 14.819

6.  Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.

Authors:  D F Woodward; A H Krauss; J W Wang; C E Protzman; A L Nieves; Y Liang; Y Donde; R M Burk; K Landsverk; C Struble
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

Review 7.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

8.  ONO-54918-07, a stable prostacyclin analogue, mimics the effect of prostaglandin PGE1 on NG108-15 cells.

Authors:  Adolfo Cavalié; Stephan Ernst Philipp; Hans Meves
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

9.  Bimatoprost effects on aqueous humor dynamics in monkeys.

Authors:  David F Woodward; Achim H-P Krauss; Siv F E Nilsson
Journal:  J Ophthalmol       Date:  2010-05-23       Impact factor: 1.909

Review 10.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.